Claims for Patent: 9,642,918

Summary for Patent: 9,642,918

Title:	Combination of inotuzumab ozogamicin and torisel for the treatment of cancer
Abstract:	The present invention relates to a therapeutic method for the treatment of cancer that comprises the use of a combination of inotuzumab ozogamicin (CMC-544) and temsirolimus. The enhanced antitumor of the combination therapy is particularly useful for patient population that are recalcitrant to inotuzumab ozogamicin or temsirolimus therapy, relapse after treatment with inotuzumab ozogamicin or temsirolimus or where enhanced antitumor effect reduces toxicities associated with treatment using inotuzumab ozogamicin or temsirolimus.
Inventor(s):	Bruederle; Andreas (Potsdam, DK), Moran; Padraig (Dublin, IE), Stathis; Anastasios (Bellinzona, CH)
Assignee:	Pfizer Inc. (New York, NY) Oncology Institute of Southern Switzerland (CH)
Application Number:	14/365,793
Patent Claims:	1. A method of treating cancer, the method comprising the step of administering to a subject in need of such treatment, either simultaneously or sequentially, an effective amount of inotuzumab ozogamicin and temsirolimus, wherein the cancer is non-Hodgkin's lymphoma, and wherein inotuzumab ozogamicin is administered at a dose of 0.4 mg/m.sup.2 to 1.8 mg/m.sup.2 every 4 weeks for 6 cycles and temsirolimus is administered at a dose of 5 to 175 mg/week until disease progression. 2. The method of claim 1 wherein inotuzumab ozogamicin and temsirolimus are administered sequentially in either order. 3. The method of claim 1, wherein the temsirolimus dose is 5 mg per week.

Details for Patent 9,642,918

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Wyeth Pharmaceuticals Llc	BESPONSA	inotuzumab ozogamicin	For Injection	761040	08/17/2017		2031-12-16